title: The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis.
abstract: The prognostic value of epidermal growth factor receptor (EGF-R) for survival of patients with lung cancer remains controversial. The authors performed a systematic review of the literature in order to clarify its impact. Published studies were identified using an electronic search in order to aggregate the available survival results, after a methodological assessment using a scale specifically designed by the European Lung Cancer Working Party (ELCWP). To be eligible, a study had to have dealt with EGF-R assessment in lung cancer patients on the primary site and to have analysed survival according to EGF-R expression. Among the 16 eligible studies, 14 assessed any nonsmall-cell lung cancer (NSCLC) subtype, one adenocarcinoma only and one squamous-cell carcinoma only. The overall median quality score was 56.3%, with no significant difference either between studies assessable or not assessable for meta-analysis or between studies with significant and nonsignificant results. One individual trial reported a survival benefit for patients with EGF-R expression, three a survival disadvantage and 12 no statistically significant difference. Eleven studies (2,185 patients) provided sufficient data to allow a meta-analysis of the survival results. EGF-R expression positivity was determined according to the cut-off as determined by the authors. The meta-analysis showed that EGF-R expression was not a statistically significant prognostic factor for survival in NSCLC. In the subgroup of studies using immunohistochemistry, statistical tests reached a significant level against EGF-R. Epidermal growth factor receptor might be a poor prognostic factor for survival in nonsmall-cell lung cancer. The amplitude of the impact is small, however, and may be subject to publication bias.
authors.affiliation: Dept of Internal Medicine, Jules Bordet Institute, Brussels, Belgium. ap.meert@bordet.be
authors.forename: A P
authors.initials: AP
authors.lastname: Meert
authors.forename: B
authors.initials: B
authors.lastname: Martin
authors.forename: P
authors.initials: P
authors.lastname: Delmotte
authors.forename: T
authors.initials: T
authors.lastname: Berghmans
authors.forename: J J
authors.initials: JJ
authors.lastname: Lafitte
authors.forename: C
authors.initials: C
authors.lastname: Mascaux
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: E
authors.initials: E
authors.lastname: Steels
authors.forename: J M
authors.initials: JM
authors.lastname: Verdebout
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology; D016009:Chi-Square Distribution; D066246:ErbB Receptors / Q000032:analysis / Q000378:metabolism*; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011336:Probability; D011379:Prognosis; D012680:Sensitivity and Specificity; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors